Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Background. Intravenous alemtuzumab and fludarabine are effective in combination for the treatment of chronic lymphocytic leukemia (CLL), but require hospital visits for intravenous injection. We performed a pilot study to assess the safety and efficacy of outpatient-based oral fludarabine with subc...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2009/547582 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850175529408266240 |
|---|---|
| author | William Y. K. Hwang Claire Dearden Yvonne S. M. Loh Yeh C. Linn Sim L. Tien Gerrard K. H. Teoh Gee F. How Kee K. Heng Yeow T. Goh Lai H. Lee |
| author_facet | William Y. K. Hwang Claire Dearden Yvonne S. M. Loh Yeh C. Linn Sim L. Tien Gerrard K. H. Teoh Gee F. How Kee K. Heng Yeow T. Goh Lai H. Lee |
| author_sort | William Y. K. Hwang |
| collection | DOAJ |
| description | Background. Intravenous alemtuzumab and fludarabine are effective in combination for the treatment of chronic lymphocytic leukemia (CLL), but require hospital visits for intravenous injection. We performed a pilot study to assess the safety and efficacy of outpatient-based oral fludarabine with subcutaneous alemtuzumab (OFSA) for the treatment of relapsed/refractory CLL. Results. Depending on their response, patients were given two to six 28-day cycles of subcutaneous alemtuzumab 30 mg on days 1,3, and 5 and oral fludarabine 40 mg/m2/day for 5 days. Median patient age was 74. The lymphocyte counts of all five patients fell after the 1st cycle of treatment and reached normal/low levels on completion of 2 to 6 cycles of therapy. Platelet counts and hemoglobin were unaffected. All five patients achieved complete hematological remission, while two attained minimal residual disease negativity on 4-color flow cytometry. Conclusions. Our OFSA regimen was effective in elderly Asian patients with relapsed/refractory CLL, and it should be investigated further. |
| format | Article |
| id | doaj-art-bfed2f99fbb24c44993abe67a038ff45 |
| institution | OA Journals |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-bfed2f99fbb24c44993abe67a038ff452025-08-20T02:19:26ZengWileyAdvances in Hematology1687-91041687-91122009-01-01200910.1155/2009/547582547582Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaWilliam Y. K. Hwang0Claire Dearden1Yvonne S. M. Loh2Yeh C. Linn3Sim L. Tien4Gerrard K. H. Teoh5Gee F. How6Kee K. Heng7Yeow T. Goh8Lai H. Lee9Department of Hematology, Singapore General Hospital, 169608, SingaporeCLL Unit, Royal Marsden Hospital, London SW3 6JJ, UKDepartment of Hematology, Singapore General Hospital, 169608, SingaporeDepartment of Hematology, Singapore General Hospital, 169608, SingaporeDepartment of Hematology, Singapore General Hospital, 169608, SingaporeDepartment of Hematology, Singapore General Hospital, 169608, SingaporeDepartment of Hematology, Singapore General Hospital, 169608, SingaporeDepartment of Hematology, Singapore General Hospital, 169608, SingaporeDepartment of Hematology, Singapore General Hospital, 169608, SingaporeDepartment of Hematology, Singapore General Hospital, 169608, SingaporeBackground. Intravenous alemtuzumab and fludarabine are effective in combination for the treatment of chronic lymphocytic leukemia (CLL), but require hospital visits for intravenous injection. We performed a pilot study to assess the safety and efficacy of outpatient-based oral fludarabine with subcutaneous alemtuzumab (OFSA) for the treatment of relapsed/refractory CLL. Results. Depending on their response, patients were given two to six 28-day cycles of subcutaneous alemtuzumab 30 mg on days 1,3, and 5 and oral fludarabine 40 mg/m2/day for 5 days. Median patient age was 74. The lymphocyte counts of all five patients fell after the 1st cycle of treatment and reached normal/low levels on completion of 2 to 6 cycles of therapy. Platelet counts and hemoglobin were unaffected. All five patients achieved complete hematological remission, while two attained minimal residual disease negativity on 4-color flow cytometry. Conclusions. Our OFSA regimen was effective in elderly Asian patients with relapsed/refractory CLL, and it should be investigated further.http://dx.doi.org/10.1155/2009/547582 |
| spellingShingle | William Y. K. Hwang Claire Dearden Yvonne S. M. Loh Yeh C. Linn Sim L. Tien Gerrard K. H. Teoh Gee F. How Kee K. Heng Yeow T. Goh Lai H. Lee Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Advances in Hematology |
| title | Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia |
| title_full | Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia |
| title_fullStr | Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia |
| title_full_unstemmed | Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia |
| title_short | Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia |
| title_sort | outpatient based therapy of oral fludarabine and subcutaneous alemtuzumab for asian patients with relapsed refractory chronic lymphocytic leukemia |
| url | http://dx.doi.org/10.1155/2009/547582 |
| work_keys_str_mv | AT williamykhwang outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia AT clairedearden outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia AT yvonnesmloh outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia AT yehclinn outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia AT simltien outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia AT gerrardkhteoh outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia AT geefhow outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia AT keekheng outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia AT yeowtgoh outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia AT laihlee outpatientbasedtherapyoforalfludarabineandsubcutaneousalemtuzumabforasianpatientswithrelapsedrefractorychroniclymphocyticleukemia |